6B – Leukemia and Oxidative Therapies Including Intravenous Ascorbic Acid / HDIVC

A seeming conundrum regarding the ability of some leukemic cells (i.e. CLL) to sequester ascorbate (ASC) has led to confusion regarding the safety and utility of high dose ascorbate delivered via IV (HDIVC). This has led to some apparent confusion between this concern and the apparent positive benefits of HDIVC seen in clinical practice.

Share:

Share on facebook
Share on twitter
Share on linkedin
Share on email

More IV Monographs

Scroll to Top